Healthcare company Perrigo Company plc (NYSE:PRGO)(TASE:PRGO) reported on Tuesday the receipt of the final approval from the US Food and Drug Administration for its AB rated Abbreviated New Drug Application (ANDA) generic Voltaren Gel, 1% (diclofenac sodium topical gel, 1%).
Voltaren Gel, a nonsteroidal anti-inflammatory drug (NSAID) in topical form, is mostly used on knees and hands, according to the company.
The US FDA approval was awarded to the company's partner, upon which, the company will acquire full ownership of the ANDA under a pre-existing arrangement with its partner within 30 days. The product is expected to be launched within the next two months.
For the 12 months ending March 2019, the annual market sales for the Voltaren Gel, 1% were approximately USD350m as measured by IQVIA.
In conjunction with the approval, the company will manufacture diclofenac sodium topical gel 1% in its plant in Israel. The product was developed through its partnership with Capstone Development Solutions, a company of Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins